Biodesix Inc. (BDSX)

Introduction

Biodesix Inc. is a publicly traded diagnostics solutions company (NASDAQ: BDSX) headquartered in Louisville, Colorado. Founded in 2005, the company develops and commercializes personalized diagnostic tests and custom development services to support early detection and treatment guidance for lung cancer and other diseases.

Corporate Structure

Leadership

• Scott Hutton, President, Chief Executive Officer, and Director
  – Led the 2020 IPO on Nasdaq
  – 25 years in biotech, diagnostics, and medical devices
  – Over 50 product launches
• John Patience, Chairman of the Board (since September 2020)
• Hany Massarany, Director (since July 2020)
• Jean M. Franchi, Director (since April 2020)
• Matthew W. Strobeck, Ph.D., Director (since January 2012)
• Jon Faiz Kayyem, Ph.D., Director (since December 2021)
• Lawrence T. Kennedy, Jr., Director
• Jack W. Schuler, Board Emeritus (as of May 2025)

Workforce and Culture

• Company size: 201–500 employees
• Operating principles: TEAM · IMPACT · EXCELLENCE
• Awards: Inc. Magazine’s Best Workplaces 2024; The Denver Post’s Top Workplaces 2025

Recent Developments and News

• May 21, 2025: Announced participation in the 22nd Annual Craig-Hallum Institutional Investor Conference.
• May 15, 2025: New data to be presented at the ISPOR 2025 Annual Meeting (Montreal) and ATS.
• May 14, 2025: Recognized as a Colorado Top Workplaces 2025 winner.
• April 29, 2025: Reported Q1 2025 financial results (period ended March 31):
  • Q1 revenue: $18.0 million (21% increase compared to Q1 2024)
  • Gross margin: 79.4%
  • Net loss improved by 18% year-over-year
  • Updated 2025 revenue guidance: $80–85 million

Financial and Strategic Analysis

Stock and Valuation Metrics (as of May 21, 2025)

Metric	Value
Stock price	$0.4096 (+51.26% compared to prior close)
Volume	16,342,025 shares
Market cap (intraday)	$39.69 million
Enterprise Value	$84.37 million
52-Week Range	$0.1720 – $2.0400
Price/Sales (ttm)	0.52
Price/Book (mrq)	3.59
Profit Margin (ttm)	–54.28%
Return on Assets (ttm)	–23.33%
Return on Equity (ttm)	–1,454.41%
Revenue (ttm)	$74.46 million
Net Income (ttm)	–$40.42 million
Cash and equivalents (mrq)	$17.6 million
Total Debt/Equity (mrq)	563.16%
Levered Free Cash Flow (ttm)	–$29.13 million

Q1 2025 Highlights

• Revenue: $18.0 million (21% increase)
• Gross margin: 79.4%
• Net loss improvement: 18% compared with Q1 2024
• FY2025 revenue guidance updated to $80–85 million

Ownership and Governance

• Jack W. Schuler and related trust beneficially own 36.33 million shares (24.7% of common stock; Schedule 13D/A filed on May 20, 2025).
• Perceptive Advisors LLC holds 7.67 million shares (5.1%; Schedule 13G filed on May 15, 2025).

Market Position and Industry Context

Biodesix operates in the lung disease diagnostics segment, offering:

• Proteomics-based assays for non-small cell lung cancer
• Multi-omics and mass spectrometry analysis
• Liquid biopsy (droplet digital PCR)
• Companion diagnostics and development services for biopharma and research institutions

The company competes with established diagnostics providers and differentiates through personalized diagnostic tests and collaborations in clinical research.

Summary

• Stock price increased by 51.26% to $0.4096 on May 21, 2025, with a trading volume of approximately 16.3 million shares.
• Q1 2025 revenue was $18.0 million, reflecting a 21% year-over-year increase; gross margin was 79.4%; net loss improved by 18%.
• FY2025 revenue guidance has been adjusted to $80–85 million.
• Major shareholder Jack W. Schuler holds a 24.7% stake according to the Schedule 13D/A filed on May 20.
• Management is scheduled to present at the Craig-Hallum conference, with new clinical and economic data to be discussed at ISPOR and ATS 2025.